oral, brain-penetrant LRRK2 kinase inhibitor

recapitulated LRRK2 lung tox. in model

discovery details manuscript in preparation

J. Pharmacol. Exp. Ther., Jan. 28, 2021

Merck & Co., Inc., Boston, MA

Chemical structure of molecule MLi-2 inhibitor

The Merck LRRK2 inhibitor, MLi-2, is an orally available tool compound that is structurally distinct from the LRRK2 inhibitor GNE-7915. LRRK2 had been a highly attractive target for treating…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: